Cambridge Healthcare Innovations announced that its Quattrii blister-based DPI has been selected for delivery of inhaled dry powder formulations of biologics being developed by University College London professor Jenny Lam. CHI partnered with Aptar in 2024 for commercialization of the Quattrii platform and recently announced that carrier-free and carrier-based versions of the device are now available for use in clinical trials.
CHI CEO David Harris commented, “Researchers are developing biologic medicines with enormous potential, but their work can be held back by a very practical problem: finding an inhaler that can handle the amount of powder they need to deliver. That is one of the problems we designed Quattrii to solve. We are delighted that Professor Lam’s team wants to use the platform. Our aim is to give formulation scientists the freedom to pursue promising medicines, with a device that supports their dose and delivery requirements. This work is an opportunity to help unlock that potential for inhaled antibodies and RNA therapeutics.”
Lam said, “Our laboratory is developing inhaled antibody and RNA therapeutics for respiratory diseases where there remains a substantial need for better treatments. We want to produce stable dry powders that have a longer shelf life and are convenient for patients, but we also need a device that can deliver the powder effectively at the doses these medicines may require. Quattrii’s combination of high powder capacity and its approach to aerosol delivery makes it well suited to the work we want to undertake.”
Read the Cambridge Healthcare announcement
